Recent enforcement action in China’s pharmaceutical industry has led to the initiation of a widespread anti-corruption push. On May 8, 2023, the National Health Commission of the People’s Republic of China (PRC) – in conjunction with 13 other government departments – issued the “Key Highlights for Combating Corruption in the Medicine Purchase and Sale Industry and Medical Services Industry for the Year 2023”. This regulation solidifies intentions to clean up and ensure transparency within the medical and pharmaceutical fields.
These measures build on a foundation of already existing anti-corruption initiatives, and exemplify the PRC’s commitment to maintaining a lawful, ethical and efficient health sector. The announcement of this concentrated effort comes amidst growing concerns around corruption in the healthcare sector, signaling a changing climate of increasingly stringent regulatory scrutiny.
International firms operating in the PRC’s pharmaceutical sector need to be aware of these developments and their potential implications. Compliance with these new regulations will require adjustments to business practices and the cultivation of comprehensive, robust anti-corruption frameworks.
To stay updated with further developments in this area, regular follow-ups can be made here.